Proteros Biostructures GmbH

https://www.proteros.de

LinkedIn: https://www.linkedin.com/company/proteros-biostructures-gmbh

Proteros is a privately-held company with expertise in structure-based drug discovery powered by a cutting-edge discovery engine tailored to unlock even the most technically challenging disease-relevant targets. The company provides small molecule drug discovery services and its comprehensive enabling technology platforms, coupled with roots to Nobel Prize winning science and the Max Planck Institute of Biochemistry, have enabled prominent contributions to several lead optimization programs and clinical-stage compounds. Proteros’ scientific rigor can accelerate overall research timelines for clients by solving the “High-hanging-fruits” of the early drug discovery and development stages and the company is consistently seen as the go-to partner for Hit to Lead Optimisation services. Proteros supports many of the world’s top 20 largest pharmaceutical companies and more than 200 pharmaceutical and biotech partners in the U.S., Europe and Japan. *

	Start	1998-01-01 established
	Group	Proteros (Group)
	Industry	structural proteomics
	Industry 2	X-ray crystallography
	Person	Neuefeind, Torsten (Proteros Biostructures 200610 Managing Director)
	Person 2	Waldmann, Thomas (Proteros 201110 Director Business Development before Sloning 200607–201108– BusDev Manager)

	Region	Martinsried
	Country	Germany
	Street	7a Bunsenstr.
	City	82152 Martinsried
	Tel	+49-89-700761-0
		Address record changed: 2023-01-09

Basic data	Employees	C: 51 to 100 (2011-08-08)

		* Document for »About Section«: Proteros Biostructures GmbH. (10/25/22). "Press Release: Proteros and Adrestia Initiate Multi-target Partnership to Discover First-in-class Drugs for Intractable Genetic Diseases". Martinsried.

		Record changed: 2025-03-16